Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Stanford Department of MedicineAudio: English

Samuel Klein on GLP-1 Revolution, Metabolism, and the Future of Obesity Medicine

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

Dr. Samuel Klein, Division Chief and William H. Danforth Professor of Medicine and Nutritional Science at Washington University Medicine, joins The Future of Medicine for a conversation about obesity, metabolism, insulin resistance, and the revolution sparked by GLP-1 medications like Ozempic. In this episode, Dr. Klein explains why obesity is far more biologically complex than many people realize — and why some individuals with obesity remain metabolically healthy while others develop diabetes, heart disease, and fatty liver disease. The conversation explores how fat functions not only as stored energy, but also as an active endocrine organ that communicates with the rest of the body through hormones and inflammatory signaling molecules. Dr. Klein discusses visceral fat, insulin resistance, inflammation, and why procedures like liposuction do not produce the same metabolic benefits as weight loss through diet, surgery, or GLP-1 medications. Dr. Klein also reflects on the unexpected rise of GLP-1 therapies, including how medications originally developed for diabetes transformed obesity treatment and may hold broader implications for cardiovascular disease, addiction, and other chronic conditions. Together, Dr. Klein and Euan Ashley discuss the future of metabolic medicine, precision approaches to obesity care, and why understanding metabolism may reshape the future of healthcare itself. Thank you for watching! 🔔 Subscribe for more conversations on groundbreaking medical science and innovation. Links: – Listen to the podcast: https://thefutureofmedicine.buzzsprout.com – Subscribe to our channel: @stanforddepartmentofmedicine Chapters 00:00 GLP-1 Therapy Impact 01:55 Obesity & Metabolism 03:43 Obesity: Not Always Bad ️ 05:11 Fat Tissue Signals 07:05 Fat: Endocrine Function 09:02 Insulin Resistance 11:29 Liposuction Studies 12:58 Visceral Fat Impact 14:31 GLP-1 Medications 16:55 GLP-1 Unexpected Use 18:30 Metabolically Healthy 20:46 Inflammation Question 22:32 Precision Medicine 25:50 Multi-Organ System 27:22 Future of Medicine

Stanford Department of Medicine · 28 min · Source published: 2026-05-25

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…